Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rifabutin + metronidazole + vonoprazan rescue therapy for Helicobacter pylori eradication
jRCTs031220504Completed
- Sponsor
- Yokohama City University
- Start
- Jan 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of rifabutin, metronidazole and vonoprazan in Helicobacter pylori infection, sponsored by Yokohama City University. Primary endpoint: Eradication rate. Started Jan 2023; status: completed.
02
Drugs
rifabutinmetronidazolevonoprazan
03
Conditions
Helicobacter pylori infection
Beyond the preview
Go deeper on jRCTs031220504.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031220504.